All
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
April 16th 2021Ayvakit demonstrated more durable survival outcomes in patients with unresectable/metastatic platelet-derived growth factor receptor A D842V-mutant gastrointestinal stromal tumors than tyrosine kinase inhibitors.
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
April 16th 2021The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.
Learning to be a Kinder Person After Cancer
April 16th 2021A cancer survivor and former military service member writes how he used to be short with people, demanded things be done his way and often made others feel little — that is until his cancer diagnosis. Here, he shares how his experience with cancer taught him to be kinder to others.
Obesity May Be Associated with Increased Cancer Mortality in Most Cancers; Lower in Others
April 14th 2021Recent study results demonstrated an possible association between a high BMI and risk of cancer and overall mortality, though patients with obesity and lung cancer, renal cell carcinoma and melanoma were found to have a lower risk of death than patients with the same cancers without obesity.
What Are the Most Common Sexual Side Effects Survivors of Cancer Face, And How Are They Treated?
April 14th 2021A study out of Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University in Philadelphia found that 87% of survivors of breast, pelvic, endometrial, prostate, bladder and rectal cancer said treatment affected their sexual function or desire.
Jakafi Reintroduced to Patients with Myelofibrosis After Discontinuation May Extend Survival
April 14th 2021Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.
How Treating Myeloma is About Extending Remissions and Making it ‘Livable’
April 12th 2021In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center discusses how she changed her perspective on finding a cure for myeloma and what her goals are when it comes to treating her patients.